GAMMA Investing LLC Has $309,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

GAMMA Investing LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 11.8% in the 4th quarter, Holdings Channel reports. The firm owned 4,286 shares of the medical equipment provider’s stock after buying an additional 454 shares during the quarter. GAMMA Investing LLC’s holdings in Hologic were worth $309,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic in the third quarter worth about $25,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in Hologic in the 2nd quarter worth approximately $37,000. First Horizon Advisors Inc. boosted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. Finally, Cromwell Holdings LLC grew its holdings in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. UBS Group raised their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Six research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Stock Up 0.8 %

HOLX opened at $73.77 on Tuesday. Hologic, Inc. has a fifty-two week low of $70.36 and a fifty-two week high of $84.67. The company has a market capitalization of $16.74 billion, a P/E ratio of 22.15, a P/E/G ratio of 2.32 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm’s fifty day moving average price is $76.59 and its two-hundred day moving average price is $78.55.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.